Abeona Therapeutics
Biotechnology Research • 
Cleveland, Ohio, United States • 201-500 Employees
Company overview
| Headquarters | 6555 Carnegie Avenue, Cleveland, OH 44103, US |
| Phone number | +16468134701 |
| Website | |
| NAICS | 541714 |
| SIC | 376 |
| Keywords | Biotechnology, Gene Therapy, Manufacturing, Cell Therapy, Rare Disease, Epidermolysis Bullosa, Pediatric Rare Diseases |
| Founded | 2015 |
| Employees | 201-500 |
| Socials |
Key Contacts at Abeona Therapeutics
Bernhardt Zeiher
Member Board Of Directors
Paul Wille
Director Of Product Development
Sara Melton
Senior Director Patient Access Cell And Gene Therapy
Rebecca Goldstein
Executive Director, Alliance Product Development
Eric Crombez
Member Board Of Directors
Trung Nguyen
Director, Contract Strategy And Operations
Eric Hartung
Regional Account Director | Cell & Gene Therapy
Ann Fiegen Durbin
Senior Director, Assay Development And Quality Control
Suzi Spayd
Sr. Director, Patient Access & Reimbursement
Curtis Bordwell
Associate Director
Abeona Therapeutics Email Formats
Abeona Therapeutics uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@abeonatherapeutics.com), used 51.4% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@abeonatherapeutics.com | 51.4% |
{first initial}{last name} | jdoe@abeonatherapeutics.com | 38.7% |
{last name}{last name} | doedoe@abeonatherapeutics.com | 6.3% |
{first initial} | j@abeonatherapeutics.com | 2.1% |
{first initial}{second initial}{last name} | jodoe@abeonatherapeutics.com | 1.4% |
About Abeona Therapeutics
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). Abeona’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.
Abeona Therapeutics revenue & valuation
| Annual revenue | $400,000 |
| Revenue per employee | $2,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $1,300,000 |
| Total funding | $120,000,000 |
Employees by Management Level
Total employees: 201-500
Seniority
Employees
Employees by Department
Abeona Therapeutics has 98 employees across 14 departments.
Departments
Number of employees
Funding Data
Explore Abeona Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Abeona Therapeutics Tech Stack
Discover the technologies and tools that power Abeona Therapeutics's digital infrastructure, from frameworks to analytics platforms.
JavaScript libraries
JavaScript libraries
UI frameworks
WordPress plugins
CDN
Web servers
JavaScript libraries
Programming languages
Security
Blogs
Analytics
Kenya
India
Australia
Mexico
Portugal
United Kingdom
ArgentinaFrequently asked questions
4.8
40,000 users
